Back to results
US 2025/0082645 A1Published application
Irak4 degraders and uses thereof
AssigneeKymera Therapeutics, Inc.
InventorsJared Gollob, Jeffrey Davis, Alice McDonald, Haojing Rong
Life of this patent
Estimating the term…
Abstract
The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.
Claims25
A spray-dried formulation comprising Compound A or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer;
- wherein Compound A is 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(difluoromethyl)-1-((1r,4R)-4-((4-((3-(1-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidin-1-yl)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
Dependencies are inferred from the claim text.